The manufacturing of Antibody-Oligonucleotide-Conjugates (AOCs) has emerged as a critical area of innovation in the development of targeted therapeutics and diagnostic tools. This novel approach is aimed at improving the efficiency, specificity, and scalability of conjugation strategies, addressing key challenges such as site-selective modification, linker stability, and product homogeneity by integrating advanced bioconjugation chemistries, optimized purification protocols, and automation-friendly workflows.

Endotoxins are glycolipids shed from gram-negative bacterial membranes. Regulatory agencies require stringent control of endotoxins in drug substance and product with tighter control for intrathecally-administered drugs. Conventional endotoxin removal relies on positively charged filters that bind negatively charged endotoxins. However, these approaches are incompatible with highly anionic antisense oligonucleotides, causing yield loss. Here, we demonstrate a hydrophobic interaction–based separation strategy that removes endotoxins from ASOs while preserving high product recovery.

This presentation explores longevity and lifestyle medicines as a growing market, focusing on challenges in large-scale biopharmaceutical manufacturing and cost-reduction strategies. It highlights advances in peptide bioprocessing and beyond, examining whether these innovations can meet rising market demands for longevity biopharmaceuticals. Emphasis is placed on optimising production efficiency and scalability to align with consumer expectations for effective, accessible, lifestyle and longevity therapies.

Manufacturing disulfide-bonded peptides in Escherichia coli offers a scalable and sustainable alternative to chemical synthesis but remains limited by proteolysis, complex folding requirements, and peptide-specific downstream development. CASPON technology provides a platform solution enabling high-titre soluble expression, affinity capture, and precise, scar-free tag removal suitable for biopharmaceutical production. By integrating outer membrane engineering, controlled peptide release into the culture medium further simplifies recovery and reduces downstream processing complexity. This combined approach minimizes process customization, shortens development timelines, and enables robust, scalable manufacturing of high-quality disulfide-bonded peptides for industrial applications.